Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sulkowski

Showing results (381-390 of 408) with videos related to

Pageof 41
Sort By:
Alimentary Pharmacology & Therapeutics|October 30, 2016
All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET databaseK R Reddy, J K Lim, A Kuo, et al.
Gastroenterology|August 12, 2019
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir TherapyAnna S Lok, Mark S Sulkowski, Jens J Kort, et al.
Hepatology International|February 18, 2017
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label studyMark S Sulkowski, Walford J Fessel, Adriano Lazzarin, et al.
Journal of Hepatology|April 17, 2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosisPaul Y Kwo, Fred Poordad, Armen Asatryan, et al.
Hepatology (Baltimore, Md.)|April 14, 2011
Racial differences in hepatitis C treatment eligibilityMichael T Melia, Andrew J Muir, Jonathan McCone, et al.
Lancet (London, England)|August 1, 2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyEric Lawitz, Mark S Sulkowski, Reem Ghalib, et al.
The American Journal of Gastroenterology|October 31, 2024
Using Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis RiskPamela M Murnane, Majid Afshar, Gabriel Chamie, et al.
JAMA|February 24, 2015
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trialMark S Sulkowski, Joseph J Eron, David Wyles, et al.
The New England Journal of Medicine|April 24, 2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsIra M Jacobson, Stuart C Gordon, Kris V Kowdley, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 20, 2020
Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swineMalvika Verma, Jacqueline N Chu, John A F Salama, et al.
Pageof 41

Showing results (381-390 of 408) with videos related to

Sort By:
Pageof 41
Alimentary Pharmacology & Therapeutics|October 30, 2016
All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET databaseK R Reddy, J K Lim, A Kuo, et al.
Gastroenterology|August 12, 2019
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir TherapyAnna S Lok, Mark S Sulkowski, Jens J Kort, et al.
Hepatology International|February 18, 2017
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label studyMark S Sulkowski, Walford J Fessel, Adriano Lazzarin, et al.
Journal of Hepatology|April 17, 2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosisPaul Y Kwo, Fred Poordad, Armen Asatryan, et al.
Hepatology (Baltimore, Md.)|April 14, 2011
Racial differences in hepatitis C treatment eligibilityMichael T Melia, Andrew J Muir, Jonathan McCone, et al.
Lancet (London, England)|August 1, 2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyEric Lawitz, Mark S Sulkowski, Reem Ghalib, et al.
The American Journal of Gastroenterology|October 31, 2024
Using Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis RiskPamela M Murnane, Majid Afshar, Gabriel Chamie, et al.
JAMA|February 24, 2015
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trialMark S Sulkowski, Joseph J Eron, David Wyles, et al.
The New England Journal of Medicine|April 24, 2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsIra M Jacobson, Stuart C Gordon, Kris V Kowdley, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 20, 2020
Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swineMalvika Verma, Jacqueline N Chu, John A F Salama, et al.
Pageof 41